Introduction {#Sec1}
============

Alzheimer's disease (AD) is the most frequent form of dementia, accounting for 50--60% of all cases (Blennow et al. [@CR5]). It is a genetically heterogeneous disease with both familial and sporadic forms. The familial forms of AD are very rare, but the few cases that exist all carry mutations that in some way affect the processing of the amyloid precursor protein (APP) in a manner that accelerates the formation of synaptotoxic amyloid β (Aβ) (Blennow et al. [@CR5]). Pathologically, AD is characterized by senile plaques containing aggregates of Aβ, and neurofibrillary tangles consisting of hyperphosphorylated tau protein. These pathological hallmarks generally debut in the hippocampus, a brain structure that is necessary for explicit learning (Salmon and Bondi [@CR36]). Consistent with hippocampal pathology, the main clinical feature in patients with AD is anterograde amnesia, and as the disease progresses, the patients also develop other cognitive symptoms (Salmon and Bondi [@CR36]). In line with these clinical findings, animal research has shown that long-term potentiation (LTP), a process that is widely believed to constitute the synaptic substrate for learning and memory (Martin et al. [@CR28]), is inhibited by low-n oligomers of Aβ (Shankar et al. [@CR38]; Townsend et al. [@CR40]; Walsh et al. [@CR46]; Klyubin et al. [@CR21]).

The mechanisms by which Aβ inhibit LTP have been elusive and several suggestions have been made (Lauren et al. [@CR22]; Li et al. [@CR23]; Origlia et al. [@CR33]; Townsend et al. [@CR41]). It has, for example, been suggested that the LTP-inhibiting effect of Aβ depend on the receptor for advanced glycation end-products (RAGE) (Arancio et al. [@CR1]; Origlia et al. [@CR32], [@CR33]). In addition, this protein has been implicated in several other aspects of AD pathology, such as inflammation, oxidative stress and transport of Aβ across the blood--brain barrier (Deane et al. [@CR10]; Schmidt et al. [@CR37]; Yan et al. [@CR47]). Together, these findings make the gene encoding RAGE (*AGER*) an interesting candidate gene for AD. Indeed, a recent Chinese case--control study presented evidence for an association between the G82S single nucleotide polymorphism (SNP) in *AGER* and AD (Li et al. [@CR24]).

The RAGE receptor is a multi-ligand receptor, and one of its ligands is Aβ (Yan et al. [@CR47]). Several intracellular pathways are activated by RAGE (Lue et al. [@CR27]), and aside from inhibiting LTP, RAGE activation can stimulate the expression of β-site APP-cleaving enzyme 1 (BACE1) (Cho et al. [@CR9]), an enzyme that is necessary for the production of Aβ. Accordingly, Aβ might exert positive feedback on its own production. Moreover, RAGE can induce its own expression through activation of the transcription factor NF-κB, and thereby initiate yet another potentially hazardous positive feedback loop (Lue et al. [@CR27]).

There is, however, another facet of RAGE; a soluble form, which is formed by alternative splicing (Ding and Keller [@CR11]) or proteolytic cleavage by the proteinase ADAM 10 (Raucci et al. [@CR35]). Soluble RAGE (sRAGE) contains the ligand-binding site, but does not have the signaling properties of full-length RAGE (flRAGE). As a result, it could act as a decoy receptor by competing with flRAGE for ligands, and thus have protective properties. Indeed, studies have shown that sRAGE can reduce the accumulation of Aβ in the brains of mice (Deane et al. [@CR10]), and that it can inhibit Aβ aggregation (Chaney et al. [@CR8]). In addition, it has been shown that sRAGE is present at lower levels in the blood and brain of AD patients (Emanuele et al. [@CR13]; Nozaki et al. [@CR31]). Whatever role is most important for the development of AD, be it the sword or the shield, remains to be seen. Either way these findings highlight *AGER* as a most interesting candidate gene for AD.

Although several susceptibility genes for AD have been identified, few have been confirmed in independent populations (Bertram and Tanzi [@CR3]). Thus, independent evaluation of the finding by Li et al. ([@CR24]) is warranted. A distinguishing feature of our study is that all AD cases were neurochemically verified, i.e., had low cerebrospinal fluid (CSF) levels of the 42 amino acid isoform of Aβ (Aβ~1--42~) as a sign of brain amyloid pathology and high levels of total tau (T-tau) as a sign of cortical axonal degeneration (Blennow et al. [@CR6]). This approach reduces the risk of including patients with other dementing illnesses in the AD group.

Subjects and methods {#Sec2}
====================

Subjects {#Sec3}
--------

The case--control material consisted of 316 AD cases and 579 controls (Table [1](#Tab1){ref-type="table"}). All individuals were of Caucasian origin. All diagnoses were set according to the National Institute of Neurological and Communicative Disorders and Stroke---Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al. [@CR29]) after detailed clinical investigation including medical history, physical, neurological and psychiatric examination, screening laboratory tests, and computed tomography of the brain. No patient had a family history of autosomal dominant dementia. For all 316 cases, previously determined AD CSF biomarker levels of T-tau and Aβ~1-42~ were available, and for a subgroup of cases (*n* = 111) P-tau~181~ levels were available as well (Table [1](#Tab1){ref-type="table"}). CSF biomarker concentrations were determined using INNOTEST ELISAs (Innogenetics, Ghent, Belgium) as described elsewhere (Blennow et al. [@CR4]; Vanderstichele et al. [@CR42]; Vanmechelen et al. [@CR43]). Clinical diagnoses were set without knowledge of the results from the biochemical and genetic analyses and vice versa. The ambition was to study a pure AD group and minimize the risk of including other dementias in the AD group. Therefore, we only included cases with a typical AD CSF biomarker profile, i.e. Aβ~42~ \< 400 pg/mL and T-tau \> 400 pg/mL (Hansson et al. [@CR17]; Zetterberg et al. [@CR48]). Controls did not have dementia and did not show any signs of psychiatric illness, malignant disease or systematic disorder. Mini-mental state examination (MMSE) scores (Folstein et al. [@CR16]) were available for most AD cases (*n* = 277) and all controls (Table [1](#Tab1){ref-type="table"}). Potential controls with MMSE scores below 28 were excluded to minimize the risk of including incipient AD cases. *APOE* ε4 carrier status was known for all cases and controls.Table 1Demographics for Alzheimer's disease cases and controlsParameterAlzheimer'sControls*P* valuesNo. of subjects316579Age (Years)76 ± 12.973 ± 4.9\<0.001Sex Female197 (62.3)416 (71.8)0.003 Male119 (37.7)163 (28.2)*APOE*-ε4 081 (25.6)430 (74.3)\<0.001 1164 (51.9)136 (23.5) 271 (22.5)13 (2.2)MMSE^a^20 ± 5.129 ± 0.7\<0.001T-tau (pg/mL)815 ± 389----P-tau~181~ (pg/mL)^b^106 ± 46----Aβ~42~ (pg/mL)256 ± 78----Data presented as *n* (%) or mean ± SD deviations*P* values were calculated with χ^2^-test for categorical parameters and Mann--Whitney *U* test for continuous parameters^a^(*n*~AD~ = 277, *n*~contr~ = 579)^b^(*n*~AD~ = 111)

Tag SNP selection {#Sec4}
-----------------

Single nucleotide polymorphism genotyping data covering *AGER* (gene ID: 177) for the European population CEU (Utah residents with ancestry from northern and western Europe) were downloaded from the HapMap Genome Browser (Phases 1 and 2---full dataset) at the International Haplotype Mapping Project web site (<http://www.hapmap.org>) (HapMap-Consortium [@CR18]) and processed in the Haploview software (Barrett et al. [@CR2]). Tag SNPs were assigned using the Tagger function (Barrett et al. [@CR2]). A minor allele frequency of ≥5% and pairwise tagging with a minimum *r*^2^ of 0.80 were applied to capture the common variations within the whole gene. The functional SNP G82S (rs2070600) was included using the "force include" option. The complete common genetic variation of *AGER* was tagged for by G82S and three additional tag SNPs: rs1800684, rs3131300 and rs1035798 (Table [2](#Tab2){ref-type="table"}).Table 2Overview of the SNPs studiedSNP^a^: *NFE2L2*Genome position^b^: Chr: 2Alleles d \> D^c^Gene locationSNP typeTaqMan assayrs180068432259972A \> TExon 1SynonymousC\_\_\_3293838_10rs313130032259912T \> CIntron 1Non-codingC\_\_11409142_10rs2070600 (G82S)32259421G \> A (82G \> 82S)Exon 3Gly→SerC\_\_15867521_20rs103579832259200T \> CIntron 3Non-codingC\_\_\_8848032_1\_^a^Presented are the genotyped SNPs arranged according to location on the gene^b^Genome positions were obtained from the HapMap Genome Browser (Phases 1 and 2---full dataset) at the International Haplotype Mapping Project web site (<http://www.hapmap.org>)^c^Alleles are given according to the sense sequence of the gene

Genotyping {#Sec5}
----------

Tag SNPs were genotyped using genomic DNA extracted from blood tissue. TaqMan^®^ Pre-Designed SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) were used (Table [2](#Tab2){ref-type="table"}) according to the TaqMan Allelic Discrimination technology (Livak [@CR25]) on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).

Statistical analyses {#Sec6}
--------------------

Statistical analyses comparing the demographics in AD cases and controls were performed with SYSTAT11 (SYSTAT Software GmbH, Erkrath, Germany) using χ^2^-test for categorical parameters and using Mann--Whitney *U* test for continuous parameters. The effects of known risk factors, e.g., sex and *APOE* ε4 were taken into consideration by identifying significantly relevant covariates for each outcome variable (disease risk, MMSE and levels of AD CSF biomarkers) using forward stepwise logistic/linear regression.

The genetic association analyses were performed using HelixTree 6.3 (Golden Helix, Bozeman, MT, USA; available at: <http://www.goldenhelix.com>). All tag SNPs were analysed for deviation from Hardy--Weinberg equilibrium. Single marker associations were performed using logistic or linear regression including relevant covariates in an additive model (SNP coded as minor allele count). Haplotype analysis was carried out using stepwise forward logistic or linear haplotype regression always keeping the identified covariates in the model. Haplotype frequencies were estimated using the expectation--maximization algorithm (Excoffier and Slatkin [@CR14]) and only haplotypes with a frequency of ≥5% were included in the analysis. Detailed description of the haplotype analyses have been given elsewhere (von Otter et al. [@CR45]). Difference in OR according to *APOE* ε4 status was tested by adding an interaction term between *APOE* ε4 and *AGER*. Corrected *P* values (*P*~c~) of ≤0.05 were considered statistically significant. To correct for multiple testing, Bonferroni correction for the number of studied SNPs was used in all single marker analyses (*n* = 4) and permutation tests with 10,000 permutations were performed in the haplotype analyses.

Ethics {#Sec7}
------

The study was approved by the ethics committees at the University of Gothenburg and the University of Lund in Sweden. The cases (or their closest relatives) and the controls gave informed consent to participate in the study, which was conducted in accordance with the provisions of the Helsinki Declaration.

Results {#Sec8}
=======

Demographics {#Sec9}
------------

Mean age and sex distribution differed between cases and controls (Table [1](#Tab1){ref-type="table"}). As expected, the *APOE* ε4 allele was strongly overrepresented in the AD group when compared with the control group (Table [1](#Tab1){ref-type="table"}). Identified covariates were sex and *APOE* ε4 for the risk association, and *APOE* ε4 alone for analysis of association with Aβ~42~ and MMSE.

SNP genotyping {#Sec10}
--------------

All markers were in Hardy--Weinberg equilibrium and had a genotyping call rate \>98%.

Association analyses {#Sec11}
--------------------

A significant association between the 82S allele (encoding amino acid Ser of the non-synonymous SNP rs2070600) and risk of AD was observed \[*P*~c~ = 0.04, OR = 2.0 (95% CI 1.2--3.4) per allele, Table [3](#Tab3){ref-type="table"}\]. When stratifying for *APOE* ε4 status, the carriers showed a significant association between the 82S allele and risk of AD \[*P* = 0.01, OR = 2.6 (95% CI 1.2--5.3\], while the non-carriers showed a weaker non-significant association \[*P* = 0.37, OR = 1.5 (95% CI 0.6--3.6) per allele, Table [4](#Tab4){ref-type="table"}\]. This OR difference was, however, not significant (*P* = 0.4) according to an interaction test between G82S and *APOE* ε4 status in the logistic regression. None of the four studied SNPs showed association with Aβ~42~, T-tau, P-tau~181~ or MMSE (data not shown). Haplotype analysis revealed no additional association with risk of AD or with any of the other studied outcomes (data not shown).Table 3SNP frequencies and associations with risk of Alzheimer's diseaseSNPGenotypeAlzheimer'sControls*P* value (*P*~c~)rs1800684TT8 (2.6)9 (1.6)0.54AT72 (23.5)150 (26.1)AA227 (73.9)416 (72.3)rs3131300CC6 (1.9)13 (2.2)0.93CT92 (29.4)167 (28.9)TT215 (68.7)398 (68.9)rs2070600AA (82S/82S)1 (0.3)0 (0.0)0.01 (0.04)AG (82S/82G)42 (13.3)35 (6.1)GG (82G/82G)273 (86.4)542 (93.9)rs1035798TT16 (5.1)48 (8.3)0.17CT115 (36.4)224 (38.7)CC185 (58.5)307 (53.0)Presented are *n* (%)At least 98% of the genotypes were successfully obtained for all SNPs as specified by the *n* numbers for the genotypesRisk associations were calculated using logistic regression in an additive model (SNP coded as minor allele count) with sex and *APOE* ε4 allele count as covariatesThe *P*~c~ value represents the Bonferroni corrected *P* value for the number of studied SNPs (*n* = 4)Table 4G82S genotype frequencies and associations after stratifying by APOE ε4 carrier statusAlzheimer'sControls*P* valueAPOE ε4 non-carriers AA (82S/82S)0 (0.0)0 (0.0)0.37 AG (82S/82G)7 (8.6)25 (5.8) GG (82G/82G)74 (91.4)404 (94.2)APOE ε4 carriers AA (82S/82S)1 (0.4)0 (0.0)0.01 AG (82S/82G)35 (14.9)10 (6.8) GG (82G/82G)199 (84.7)138 (93.2)Presented are *n* (%)Risk associations were calculated using logistic regression in an additive model (SNP coded as minor allele count) with sex as a covariate

Discussion {#Sec12}
==========

In the present European case--control study, we show that the G82S SNP (rs2070600) in *AGER*, the gene encoding RAGE, is associated with increased risk of AD (*P*~c~ = 0.04, OR = 2.0, 95% CI 1.2--3.4, *n* = 893). This finding corroborates the finding of Li et al. ([@CR24]), who showed that the G82S SNP in *AGER* was associated with AD diagnosis in a Chinese case--control study. They reported an OR of approximately 1.5, which is slightly lower than reported here. These results reinforce each other and suggest that *AGER* indeed is a susceptibility gene for AD. The lack of association of the synonymous SNP (rs1800684) is in line with previously published data (Blomqvist et al. [@CR7]; Emahazion et al. [@CR12]) while the other SNPs have not been previously analysed regarding risk of AD.

In the study by Li et al. ([@CR24]) the risk association of 82S carriers with AD (OR = 1.6) was found significant among the *APOE* ε4 non-carriers, but slightly weaker (OR = 1.4) and not significant among the smaller group of *APOE* ε4 carriers. When analyzing the difference in these two ORs by adding an interaction term in a logistic regression model, no significant deviation was found. The G82S effect on risk of AD differed slightly according to *APOE* ε4 status in our study as well. However, we had a significant effect (OR = 2.6) among the *APOE* ε4 carriers, but a weaker non-significant effect (OR = 1.5) in the *APOE* ε4 non-carrier group. The difference between our two ORs was also not significant. Taken together, the two studies indicate that the risk associated with G82S is independent of *APOE* ε4 status. The lack of association of *AGER* SNPs with CSF biomarkers for neuropathological changes in AD and MMSE scores may be considered reasonable in the light of the small effect size of *AGER* G82S on disease risk.

What biological effects of a single amino acid substitution in RAGE may explain the association with AD? First, RAGE may affect both production and accumulation of Aβ in the brain (Chaney et al. [@CR8]; Cho et al. [@CR9]; Deane et al. [@CR10]). Because the G82S SNP is located in an exon that codes for the ligand-binding site, it is possible that the observed effect is related to ligand binding. The 82S variant has been shown to increase the ligand-binding affinity of the receptor (Hofmann et al. [@CR19]; Osawa et al. [@CR34]). This could potentially lead to an increased signaling, which in turn, would accelerate APP processing through BACE1 \[since BACE1 has been shown to be positively regulated by RAGE (Cho et al. [@CR9])\], and thereby increase Aβ production. In addition, an increased transport of circulating Aβ into the brain would be expected because RAGE has been shown to transport Aβ across the blood--brain barrier into the brain (Deane et al. [@CR10]). It seems unlikely that this is how the 82S variant increases the risk for AD though, since we found no association between G82S genotype and Aβ levels. The 82S variant may on the other hand be more effective in mediating the LTP-inhibiting effect of Aβ (Arancio et al. [@CR1]; Origlia et al. [@CR32], [@CR33]), a hypothesis that remains to be tested.

It is not entirely obvious that a higher affinity for ligand binding should lead to an increased risk for AD since sRAGE should also be affected, and hence, have an increased propensity to scavenge Aβ, thus increased protective properties. Nevertheless, this is not the case and an explanation could be that flRAGE is engaged in positive feedback mechanisms, thereby enhancing its own production, thus giving little room for sRAGE to exert its proposed protective mechanisms. This notion is supported by the finding that flRAGE expression is increased in AD brains (Lue et al. [@CR26]; Miller et al. [@CR30]). In addition, it has been shown that 82S carriers have roughly half as much circulating sRAGE when compared with 82G carriers (Jang et al. [@CR20]; Li et al. [@CR24]), implying that the increased ligand affinity of the receptor leads to a dysregulation of RAGE isoforms. In this context, it is interesting to note that we found no association between G82S genotype and Aβ levels in CSF, since it implies that the protective properties of sRAGE observed in animal models of AD may be of limited clinical relevance.

It was recently shown that *AGER* deletion leads to lower levels of Aβ in 6 months old mice carrying the familial Arctic (Arc) and Swedish (Swe) AD mutations. Interestingly, this was not the case for 12 months old animals, and surprisingly neither the 6 months nor 12 months old knockout animals performed better than the control Arc/Swe animals in a Y-maze memory test (Vodopivec et al. [@CR44]). This is in conflict with the results from Fang et al. ([@CR15]) showing that deletion of the intracellular signaling domain in RAGE (dominant negative, DN-RAGE) has a protective effect on memory function. One explanation for these contradicting results could be that the two studies used different memory testing paradigms. Another explanation could be that DN-RAGE still has the possibility to form sRAGE. A third piece in this knockout puzzle is the study by Takuma et al. ([@CR39]) which showed that deletion of *AGER* reduced the amount of intracellular Aβ, p38 MAPK phosphorylation and Aβ-induced mitochondrial dysfunction in cultured cortical neurons. To summarize, it seems like deletion of *AGER* leads to reduction in Aβ and its related pathology. The results on Aβ levels by Vodopivec et al. might be due to the highly pathogenic Arc/Swe mutations, and might also suggest that RAGE is mainly a contributing factor in the disease process highlighting the importance of RAGE in the acquisition of sporadic AD. If this is the case, one would expect age at onset to be affected. Unfortunately, this analysis was not possible to perform in our material, but it would be a valuable addition in future replication studies.

Aside from the importance of identifying genetic risk factors, which might aid future therapeutic strategies, and early diagnosis, gene association studies constitute a bridge between experimental animal research aiming in understanding the mechanisms of disease, and clinical research on the actual patients whom the experimentalists aim to aid, thereby lending further support to the findings made in animal models of the disease. This is of great importance since a lot of effort is put into understanding the etiology of different diseases. By showing associations between disease and a gene under intense study, we can confirm that the clues found in experimental model systems are relevant to the disease under study, and thus, should be further pursued.

In conclusion, our data, together with the findings by Li et al. speak for a weak, but significant effect of *AGER* on risk of AD. Further studies on independent and larger cohorts are highly desired, as is the exploration of a possible association of *AGER* G82S with age at onset of AD.
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